• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
A Survey of Patient Experience in CML: American and Canadian Perspectives.慢性粒细胞白血病患者体验调查:美国和加拿大视角
Patient Prefer Adherence. 2023 Feb 3;17:331-347. doi: 10.2147/PPA.S394332. eCollection 2023.
2
Chronic myeloid leukemia (CML): association of treatment satisfaction, negative medication experience and treatment restrictions with health outcomes, from the patient's perspective.慢性髓细胞白血病(CML):从患者角度看治疗满意度、负面药物体验和治疗限制与健康结局的关联。
Health Qual Life Outcomes. 2013 Oct 8;11:167. doi: 10.1186/1477-7525-11-167.
3
Symptom Burden and Quality of Life Issues among Patients of Chronic Myeloid Leukemia on Long-term Imatinib Therapy.长期接受伊马替尼治疗的慢性髓性白血病患者的症状负担与生活质量问题
Indian J Med Paediatr Oncol. 2017 Apr-Jun;38(2):165-168. doi: 10.4103/ijmpo.ijmpo_160_16.
4
Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.在流行地区,服用抗叶酸抗疟药物的人群中,叶酸补充剂与疟疾易感性和严重程度的关系。
Cochrane Database Syst Rev. 2022 Feb 1;2(2022):CD014217. doi: 10.1002/14651858.CD014217.
5
Quality of Life and Symptom Burden With First- and Second-generation Tyrosine Kinase Inhibitors in Patients With Chronic-phase Chronic Myeloid Leukemia.初、二代酪氨酸激酶抑制剂治疗慢性期慢性髓性白血病患者的生活质量和症状负担。
Clin Lymphoma Myeloma Leuk. 2020 Dec;20(12):836-842. doi: 10.1016/j.clml.2020.08.009. Epub 2020 Aug 18.
6
Improving Sexual and Gender Minority Cancer Care: Patient and Caregiver Perspectives From a Multi-Methods Pilot Study.改善性少数群体和性别少数群体的癌症护理:一项多方法试点研究中患者和护理人员的观点
Front Oncol. 2022 May 6;12:833195. doi: 10.3389/fonc.2022.833195. eCollection 2022.
7
8
A prospective analysis of symptom burden for patients with chronic myeloid leukemia in chronic phase treated with frontline second- and third-generation tyrosine kinase inhibitors.一项前瞻性分析慢性期慢性髓性白血病患者一线二代和三代酪氨酸激酶抑制剂治疗后的症状负担。
Cancer Med. 2018 Nov;7(11):5457-5469. doi: 10.1002/cam4.1808. Epub 2018 Oct 14.
9
Palliative care experiences of adult cancer patients from ethnocultural groups: a qualitative systematic review protocol.不同种族文化群体成年癌症患者的姑息治疗体验:一项定性系统评价方案
JBI Database System Rev Implement Rep. 2015 Jan;13(1):99-111. doi: 10.11124/jbisrir-2015-1809.
10
Patient-reported long-term outcome following allogeneic hematopoietic stem cell transplantation in pediatric chronic myeloid leukemia.儿童慢性髓性白血病异基因造血干细胞移植后的患者报告长期结局
Front Oncol. 2022 Sep 29;12:963223. doi: 10.3389/fonc.2022.963223. eCollection 2022.

本文引用的文献

1
Real-World Analysis of the Therapeutic Management and Disease Burden in Chronic Myeloid Leukemia Patients with Later Lines in Italy.意大利慢性髓性白血病后线治疗管理与疾病负担的真实世界分析
J Clin Med. 2022 Jun 22;11(13):3597. doi: 10.3390/jcm11133597.
2
Health-Related Quality of Life of Patients with Chronic Myeloid Leukemia as Measured by Patient-Reported Outcomes: Current State and Future Directions.患者报告结局测量的慢性髓性白血病患者的健康相关生活质量:现状与未来方向。
Curr Hematol Malig Rep. 2021 Dec;16(6):491-499. doi: 10.1007/s11899-021-00656-y. Epub 2021 Oct 14.
3
Patient-Reported Functional Outcomes in Patients With Chronic Myeloid Leukemia After Stopping Tyrosine Kinase Inhibitors.慢性髓性白血病患者停止酪氨酸激酶抑制剂治疗后的患者报告功能结局。
J Natl Cancer Inst. 2022 Jan 11;114(1):160-164. doi: 10.1093/jnci/djab184.
4
Filling the gaps of patient information needs and information perception in chronic myeloid leukemia with the patient-physician co-produced web-based platform CMyLife.利用医患共同参与研发的网络平台 CMyLife 填补慢性髓性白血病患者信息需求和信息感知方面的空白。
Patient Educ Couns. 2022 Mar;105(3):686-694. doi: 10.1016/j.pec.2021.06.025. Epub 2021 Jun 27.
5
Third-line therapy for chronic myeloid leukemia: current status and future directions.慢性髓性白血病的三线治疗:现状与未来方向。
J Hematol Oncol. 2021 Mar 18;14(1):44. doi: 10.1186/s13045-021-01055-9.
6
Assessment of Outcomes After Stopping Tyrosine Kinase Inhibitors Among Patients With Chronic Myeloid Leukemia: A Nonrandomized Clinical Trial.酪氨酸激酶抑制剂停药后慢性髓性白血病患者结局评估:一项非随机临床试验。
JAMA Oncol. 2021 Jan 1;7(1):42-50. doi: 10.1001/jamaoncol.2020.5774.
7
Chronic Myeloid Leukemia in 2020.2020年的慢性髓系白血病。
Hemasphere. 2020 Sep 30;4(5):e468. doi: 10.1097/HS9.0000000000000468. eCollection 2020 Oct.
8
Treatment-free remission in chronic myeloid leukemia: the patient perspective and areas of unmet needs.慢性髓性白血病的无治疗缓解:患者视角和未满足需求领域。
Leukemia. 2020 Aug;34(8):2102-2112. doi: 10.1038/s41375-020-0867-0. Epub 2020 May 26.
9
Experiences of living with chronic myeloid leukaemia and adhering to tyrosine kinase inhibitors: A thematic synthesis of qualitative studies.与慢性髓性白血病共存并坚持使用酪氨酸激酶抑制剂的体验:定性研究的主题综合分析。
Eur J Oncol Nurs. 2020 Apr;45:101730. doi: 10.1016/j.ejon.2020.101730. Epub 2020 Feb 11.
10
European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia.欧洲白血病网络 2020 年治疗慢性髓性白血病的建议。
Leukemia. 2020 Apr;34(4):966-984. doi: 10.1038/s41375-020-0776-2. Epub 2020 Mar 3.

慢性粒细胞白血病患者体验调查:美国和加拿大视角

A Survey of Patient Experience in CML: American and Canadian Perspectives.

作者信息

Hillis Christopher, Flynn Kathryn E, Goldman Erinn Hoag, Moreira-Lucas Tracy S, Visentini Josie, Dorman Stephanie, Ballinger Rachel, Byrnes Hilary F, De Palma Andrea, Barbier Valentin, Machado Lisa, Atallah Ehab

机构信息

Department of Oncology, McMaster University, Hamilton, Canada.

Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA.

出版信息

Patient Prefer Adherence. 2023 Feb 3;17:331-347. doi: 10.2147/PPA.S394332. eCollection 2023.

DOI:10.2147/PPA.S394332
PMID:36760231
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9904222/
Abstract

PURPOSE

With treatment, chronic myeloid leukemia (CML) has a favorable prognosis, however, individuals with CML experience impairment to their quality of life (QoL). The aim of this study was to examine the perspectives and experiences of individuals with CML and to understand their challenges communicating with their CML physician.

PATIENTS AND METHODS

An online survey in adults with CML (n=100) in the US and Canada assessed QoL, patient-provider relationships, treatment satisfaction, and understanding of CML and treatment goals via the MD Anderson Symptom Inventory, the Cancer Therapy Satisfaction Questionnaire and de novo survey questions. Participants were recruited via an external patient recruiter and CML Patient Groups.

RESULTS

Many participants reported hardships due to CML and its treatment. The main impacts were on the ability to work (21%), engage in personal activities (e.g., hobbies, 28%), and to enjoy sexual relations (median=2.00, IQR=8.50). A substantial proportion (21-39%) wished to discuss additional topics with their providers (e.g., management of CML and/or its impacts). While participants reported satisfaction with therapy overall (median=85.71, IQR=17.86), they indicated low to moderate treatment satisfaction with specific components, including concerns regarding side effects (median=43.75, IQR=43.75). Participants generally had a good understanding of CML (97%) and its treatment goals (92%).

CONCLUSION

These findings advance our understanding of issues that need improvement to support QoL for individuals living with CML. Future work is needed to improve patient-provider relationships, address treatment-related side effects, and provide clinical information that is easier for patients to understand.

摘要

目的

经过治疗,慢性髓性白血病(CML)的预后良好,然而,CML患者的生活质量(QoL)会受到损害。本研究的目的是调查CML患者的观点和经历,并了解他们与CML医生沟通时所面临的挑战。

患者与方法

在美国和加拿大对100名成年CML患者进行了一项在线调查,通过MD安德森症状量表、癌症治疗满意度问卷和新设计的调查问题,评估了生活质量、患者与医疗服务提供者的关系、治疗满意度以及对CML和治疗目标的理解。参与者通过外部患者招募机构和CML患者群体招募。

结果

许多参与者报告了CML及其治疗带来的困难。主要影响在于工作能力(21%)、参与个人活动(如爱好,28%)以及享受性关系的能力(中位数=2.00,四分位距=8.50)。相当一部分人(21 - 39%)希望与他们的医疗服务提供者讨论其他话题(如CML的管理和/或其影响)。虽然参与者总体上对治疗表示满意(中位数=85.71,四分位距=17.86),但他们对特定方面的治疗满意度较低至中等,包括对副作用的担忧(中位数=43.75,四分位距=43.75)。参与者总体上对CML(97%)及其治疗目标(92%)有较好的理解。

结论

这些发现增进了我们对需要改进的问题的理解,以支持CML患者的生活质量。未来需要开展工作来改善患者与医疗服务提供者的关系,解决与治疗相关的副作用,并提供更易于患者理解的临床信息。